medical devices

Medtronic plc (NYSE:MDT) reported fourth-quarter 2025 sales of $8.93 billion, beating the consensus of $8.82 billion. The medical device maker reported: Adjusted EPS of $1.62, beating the consensus of $1.58. A year-over-year revenue increase of 3.9% and 5.4% Y/Y organically. Cardiovascular segment...

Becton Dickinson, and Company (NYSE:BDX) lowered its fiscal year 2025 guidance and provided an estimated tariff impact on Thursday. The medical device company reported adjusted earnings per share of $3.35, up from $3.17 a year ago. It beat the consensus of $3.28. The company reported first-quarter...

On Thursday, Baxter International Inc. (NYSE:BAX) reported a first-quarter 2025 adjusted EPS of 62 cents, beating the management guidance of 47 to 50 cents and the Wall Street estimate of 48 cents. The medical device company reported sales of $2.63 billion. That’s up 5% year over year on both...

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless...

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With...

ICU Medical Inc's (NASDAQ:ICUI) subsidiary, Smiths Medical, initiated a recall Friday of its paraPAC plus P300 and P310 ventilators due to faulty parts. According to the FDA, there’s a possibility that the patient outlet connector may loosen or detach, impacting active ventilation. If this...

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With...

Johnson & Johnson (NYSE: JNJ) reported its third quarter results that topped Wall Street’s expectations while also lifting its full year guidance fueled by a strong performance of its pharmaceutical and medical devices businesses. This is the company’s first quarterly report since...

Enabling tech is likely to continue driving Globus Medical Inc’s (NYSE: GMED) market share gains in 2022, according to BofA Securities. The Globus Medical Analyst: Craig Bijou upgraded the rating for Globus Medical from Underperform to Buy, while raising the price target from $55 to $80. The...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Abbott Laboratories (NYSE: ABT) traded today at a new 52-week high of $129.40. Approximately 642,000 shares have changed hands today, as...

Glaukos Corp (NYSE: GKOS) has submitted a supplemental premarket approval (PMA) application to the FDA for its iStent infinite Trabecular Micro-Bypass System. Related Content: William Blair Downgrades Glaukos After Disappointing CMS Rate The iStent infinite is an...

Johnson & Johnson (NYSE: JNJ) announced recently a change in leadership with Alex Gorsky stepping down from his CEO role and handing the reigns to Joaquin Duato, who will take over on Jan. 3, 2022. Here are five things you might not know about Joaquin Duato, the next CEO of Johnson...

A SPAC led by the founder of Memic Innovative Surgery and several experienced medical device company executives has announced its merger partner.  The SPAC Deal: Memic Innovative Surgery announced a SPAC merger with MedTech Acquisition Corp (NASDAQ: MTAC) Friday. The merger...

Study results from a glucose monitoring company were reported after market close Thursday. What Happened: Medical technology company Senseonics Holdings (NYSE: SENS) reported results from a PROMISE study evaluating its Eversense CGM System for up to 180 days. The Eversense CGM is a continuous...

Boston Scientific Corporation (NYSE: BSX) delivered a first-quarter miss  in April and adjusted its 2019 guidance. The stock holds several catalysts this year, including the FDA paclitaxel panel, a pipeline update at the company’s analyst meeting in June and the closing of the BTG...